MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing SLK, a tri-specific Nanobody designed to inhibit IL-17A and IL-17F for inflammatory skin and joint diseases. The company has no approved products or product revenue yet and is preparing for late-stage regulatory filing and potential commercialization, initially in hidradenitis suppurativa and related inflammatory indications.

9.27

9.27

— MoonLake Immunotherapeutics
%
Lead drug candidate100% SLK is the company's single proprietary therapeutic candidate for inflammatory skin and joint diseases.
Clinical development programs0% Ongoing and planned trials in HS, PsA, adolescent HS, axSpA and PPP support the lead asset's label expansion.
Regulatory and commercialization readiness0% Activities include BLA preparation, manufacturing planning, and launch infrastructure build-out.

MoonLake does not yet sell commercial products, so its near-term 'customers' are regulators, clinical investigators,...

  • Regulatorsprimary

    FDA, EMA and other agencies review clinical data and determine whether SLK can be marketed.

  • Dermatology specialistsprimary

    Dermatologists treating moderate-to-severe HS would prescribe SLK if it is approved and differentiated on efficacy or durability.

  • Rheumatology specialistssecondary

    Rheumatologists treating PsA and axSpA are future prescribers for label expansion beyond HS.

  • Third-party payorsprimary

    Insurers and reimbursement bodies will influence uptake because the product is expected to compete at a premium price.

  • Clinical trial sites and investigatorsprimary

    Hospitals, clinics and investigators run the studies that generate the evidence needed for approval.

MoonLake is headquartered in Zug, Switzerland, but is organized as a Cayman Islands company and operates a...

  • •Headquarters in Zug, Switzerland
  • •Cayman Islands parent structure with Swiss operating roots
  • •Clinical and regulatory focus in the United States and Europe
  • •Office leases in Zug, Cambridge and Porto support operations
  • •Planned first commercial launch is expected in the U.S.

The company is focused on completing late-stage development of SLK, filing a BLA, and building the operational...

01
Advance SLK through late-stage clinical developmentshort-term

Approval depends on successful Phase 3 data and a clean safety profile in the target inflammatory indications.

02
Prepare regulatory submission and launch readinessshort-term

The company needs to convert clinical data into a BLA and establish the commercial infrastructure for first sales.

03
Strengthen intellectual property and exclusivitymedium-term

A single-asset biotech depends on patent protection and license durability to preserve future pricing power and value.

04
Broaden pipeline optionalitymedium-term

Additional indications or assets could reduce concentration risk and extend the company's growth runway.

MoonLake is highly dependent on a single clinical asset, so trial failure, safety issues, or regulatory setbacks would...

critical

Clinical development failure for SLK

The company has no approved products and depends on positive Phase 3 outcomes to create value.

Scope
HS, PsA, adolescent HS, PPP and axSpA programs
Materiality
high
high

Safety or tolerability issues

An unfavorable safety profile could prevent approval or reduce physician and payer adoption.

Scope
All SLK indications
Materiality
high
high

License and IP dependence

Rights to SLK are licensed, so breach or failure to meet diligence obligations could impair commercialization rights.

Scope
MHKDG and RCT license arrangements
Materiality
high
high

Financing and dilution risk

Development and launch spending exceed current operating cash generation, so future funding may be required.

Scope
Pre-commercial R&D and launch build-out
Materiality
high
high

Manufacturing and supply chain risk

The company relies on third parties for SLK production and clinical supply.

Scope
Contract manufacturing and clinical supply chain
Materiality
medium
medium

Commercial adoption and reimbursement risk

SLK is expected to launch at a premium price, which may slow uptake versus established biologics and biosimilars.

Scope
Future U.S. and ex-U.S. launch
Materiality
medium
Revenue recognition
No current sales base; future periods may be volatile when commercialization begins
Research and development accruals
Can shift quarterly operating loss and cash burn
Share-based compensation
Affects reported loss and per-share metrics
Contractual commitments
Important for future cash requirements
Lease and debt accounting
Affects leverage, liquidity and future cash flows

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

IOVANCE BIOTHERAPEUTICS, INC.

IOVA · Biological Products, (No Diagnostic Substances)

Estrella Immunopharma, Inc.

ESLA · Biological Products, (No Diagnostic Substances)

AIM ImmunoTech Inc.

AIM · Biological Products, (No Diagnostic Substances)

Immunocore Holdings plc

IMCR · Biological Products, (No Diagnostic Substances)

Janux Therapeutics, Inc.

JANX · Pharmaceutical Preparations

: 28.4.2026